The Role of Advanced Technologies Supplemented with Traditional Methods in Pharmacovigilance Sciences

Abstract

Background: The immediate automatic systemic monitoring and reporting of adverse drug reaction, improving the efficacy is the utmost need of medical informatics community. The venturing of advanced digital technologies into the health sector has opened new avenues for rapid monitoring. In recent years, data shared through social media, mobile apps and on other social websites has increased manifolds requiring data mining techniques. Objective: The objective of this report is to highlight the role of advanced technologies together with traditional methods to proactively aid in early detection of adverse drug reactions concerned with drug safety and pharmacovigilance. Methods: A thorough search was conducted for papers and patents regarding pharmacivigilance. All articles with respect to relevant subject were explored and mined from public repositories such as Pubmed, Google Scholar, Springer, ScienceDirect (Elsevier), Web of Science, etc. Results: The European Union’s Innovative Medicines Initiative WEB-RADR project emphasized the development of mobile applications and social media data for reporting adverse effects. Only relevant data has to be captured through the data mining algorithms (DMAs) playing an important role in timely prediction of risk with high accuracy using two popular approaches the frequentist and Bayesian approach. The pharmacovigilance at premarketing stage is useful for the prediction of the adverse drug reactions in early developmental stage of a drug. Later postmarketing safety reports and clinical data reports are important to be monitored through electronic health records, prescription-event monitoring, spontaneous reporting databases, etc approaches. Conclusion: The advanced technologies supplemented with traditional technologies is the need of hour for evaluating product’s risk profile and reducing risk in population esp. with comorbid conditions and on concomitant medications.

Mobile apps for quick adverse drug reaction report: A scoping review

“…While use of the app to date seems modest in comparison with other ADR‐reporting modalities, it is reasonable to expect that app‐based reporting will grow in importance as a younger generation increasingly use their mobile devices to access the Internet all around the world. It can be expected that apps will supplement the traditional technologies for evaluating a product's risk profile, as quality seems not to significantly differ, but the profile of reporters and cases seem to present some differences 38,49 . All the seven sins of Inman are certainly not overcome with the use of apps, but studies point to the fact that additional information can be obtained on drug's safety profile with the use of such means, namely due to new reporters with different profiles 50 …”

“…It can be expected that apps will supplement the traditional technologies for evaluating a product's risk profile, as quality seems not to significantly differ, but the profile of reporters and cases seem to present some differences. 38,49 All the seven sins of Inman are certainly not overcome with the use of apps, but studies point to the fact that additional information can be obtained on drug's safety profile with the use of such means, namely due to new reporters with different profiles. 50 Besides the ADR-reporting component, all apps presented a safety information-provision component as well.…”

Exploratory data analysis of physicochemical parameters of natural antimicrobial and anticancer peptides: Unraveling the patterns and trends for the rational design of novel peptides

“…The datasets analyzed for deducing statistical patterns and different graphical representations were also plotted for visual analysis of data. [37][38][39][40][41][42][43] EDA of natural AMPs and ACPs datasets can provide insight into the design parameters. In addition, the uncertainty in physicochemical parameters of some AMPs that have shown anticancer activity can also be inferred to develop new potent AMPs or ACPs.…”